DAPAGLIFLOZIN
Information current as at: 1 June 2025
PBAC meeting date: July 2021
Submission Details
- Brand name:
-
- Forxiga®
- Pharmaceutical company:
- AstraZeneca Pty Ltd
- Condition/indication:
(therapeutic use) -
- Chronic kidney disease
- PBAC Submission type:
- Change to listing (Category 1-2)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2021
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 21/03/2021 and close 26/05/2021 (see PBS Website)
-
PBAC meeting: - Held on 07/07/2021
-
PBAC outcome published: - Deferred (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a346
Page last updated: 31 October 2024